Not medical advice. Talk to your provider before using any peptide.
Full disclaimerEpithalon vs GHK-Cu
Peptide Schedule Research TeamReviewed Apr 202620 Citations
Side-by-side comparison of dosage, benefits, and side effects.
A 2025 paper changed the conversation around this peptide. Al-Dulaimi and colleagues replicated epithalon's telomere elongation effect in human cell lines (PMID 40908429), confirming telomerase upregulation independent of Khavinson's lab for the first time. Epithalon (epitalon, molecular weight 390.35 Da) is a synthetic tetrapeptide modeled after epithalamin, a pineal gland extract. It activates telomerase, the enzyme that adds TTAGGG repeats to chromosome ends. Short telomeres push cells into senescence or death. Restoring telomerase activity, at least in theory, reverses that clock. The practical picture is more complicated. Every published human observation comes from Khavinson's own unblinded cohorts in elderly Russian populations during the 1990s and 2000s. No randomized controlled trial exists. A 2025 IJMS review (PMID 40141547) noted explicitly that safety information on this peptide is missing. Community use tells a different story. Hundreds of users across peptide forums run 10-day cycles twice per year and report rapid sleep improvement, typically by day 3 to 5. That effect operates through pineal melatonin normalization, a faster and better-understood mechanism than telomere extension. Deeper sleep, fewer awakenings, and improved morning energy are the most reproducible outcomes. The telomere claim itself is taken largely on faith since no practical at-home marker exists; telomere testing before and after multiple cycles is the only objective route, and single-measurement variability is large. At roughly $33 to $50 per 10-day cycle, epithalon is one of the cheapest peptides in the longevity space. Epithalon was on the FDA Category 2 list until April 15, 2026. PCAC review begins July 2026. All current supply is research-grade.
View full guide →Four thousand genes. That's the number GHK-Cu flips toward repair when it binds to human cells, according to gene expression profiling by Pickart's group (PMID 25789553, 26236730). The GHK-Cu peptide (glycyl-L-histidyl-L-lysine copper(II), also written GHK:Cu or copper tripeptide-1) is a naturally occurring copper peptide found in human plasma, saliva, and urine. Plasma levels sit around 200 ng/mL at age 20 and drop to roughly 80 ng/mL by age 60. The mechanism is broad. GHK-Cu upregulates collagen I, III, and V synthesis, boosts elastin and decorin production, and recruits immune and endothelial cells to damaged tissue. The copper ion itself is required for enzymatic processes in wound remodeling. In 2024, Bian and colleagues confirmed anti-fibrotic activity in a silicosis lung model with human biomarker data (PMID 38879894), expanding the peptide's research footprint beyond skin. In practice, two routes dominate. Topical formulations (1 to 3% concentration) have cosmetic safety data going back decades; small clinical trials (n = 41 to 71) showed improved skin density and fine line reduction. Injectable use (0.5 to 2 mg/day subcutaneous) has no published dose-finding trial in humans but has one of the largest community evidence bases of any anti-aging peptide. Reports across r/Peptides, r/Biohackers, and practitioner networks describe improved skin firmness by weeks four to six; sentiment runs at 4.2 out of 5. The honest limitation: all mechanistic data is in vitro or murine. Pro-angiogenic activity flagged by the NCI raises an unresolved theoretical oncology concern. GHK-Cu is classified as research-only and is not FDA-approved for any indication.
View full guide →At a Glance
| Attribute |  Epithalon |  GHK-Cu |
|---|---|---|
| Category | Anti-Aging | Anti-Aging |
| Safety Grade | B | A |
| Half-Life | ~30 minutes (plasma) | ~1 hour |
| Route | Subcutaneous or Intramuscular | Subcutaneous or Topical |
| Vial Sizes | 10mg | 5mg, 50mg |
| Beginner Dose | 5000mcg Daily | 1000mcg Daily |
| Moderate Dose | 10000mcg Daily | 2500mcg Daily |
| Aggressive Dose | 10000mcg Daily | 3000mcg Daily |
| Dosing Source | Community | Community |
| Side Effects | The biggest concern with epithalon isn't a side effect you'll feel. It's a theoretical risk you can't observe. Telomerase reactivation is a hallmark of cancer cell immortalization. Khavinson's rodent studies actually showed reduced tumor rates with epithalon, but Al-Dulaimi's 2025 paper found ALT pathway activation in cancer cell lines (PMID 40908429). That's a new signal. Anyone with active cancer or a cancer history should treat this as a hard stop. A 2025 IJMS systematic overview (PMID 40141547) stated explicitly that "information regarding critical issues about this peptide's safety is missing." The total human safety database is small, uncontrolled, and comes almost entirely from one research group. Published side effects from Khavinson's cohort studies: none reported beyond injection site reactions. That's a limitation of the data, not proof of safety. Unblinded observational studies in elderly populations are not designed to catch adverse events with any rigor. Community-reported effects paint a more complete picture. Injection site redness is common and expected for subcutaneous peptide administration. Rotate between abdomen and deltoid over a 10-day cycle. Redness spreading beyond the immediate injection area or lasting more than 24 hours warrants stopping. Vivid dreams and occasionally nightmares are reported by a minority of users. This tracks with the melatonin mechanism; improved melatonin output alters REM sleep architecture. It usually settles within a few days. Dropping to 5 mg/day helps if dreams become disruptive. Daytime drowsiness can occur, particularly if you're stacking epithalon with exogenous melatonin, magnesium, GABA, or valerian. The combination over-sedates. Reduce the dose or shift injection earlier in the evening. Contraindications: pregnancy or breastfeeding, active cancer or cancer history, known hypersensitivity to any of the four amino acid components, autoimmune conditions (use with medical supervision only), and children or adolescents (no safety data). Immunosuppressant users need close monitoring since epithalon may modulate immune function. Anyone on chemotherapy or anti-telomerase agents (imetelstat, BIBR 1532) faces a direct mechanistic conflict. Stop immediately if any unexplained mass or growth appears. Discontinue if cancer is diagnosed at any point during use. Stop if sleep paradoxically worsens. Do not extend cycles beyond 20 days. | The most serious concern with GHK-Cu is its pro-angiogenic activity. The NCI flagged this years ago: a peptide that promotes new blood vessel formation could, in theory, support tumor vascularization. No human case has confirmed this, but no study has ruled it out either. Anyone with an active malignancy should not use GHK-Cu without oncologist clearance. Copper toxicity is the second concern worth taking seriously. At typical community doses (1 to 2 mg/day subcutaneous), the copper load stays well below toxic thresholds. But continuous long-term use without lab monitoring creates an accumulation risk. Wilson's disease, hemochromatosis, and any copper metabolism disorder are absolute contraindications. Symptoms of copper excess include nausea, metallic taste, and jaundice; if these appear, stop immediately and get serum copper checked. Published side effects in topical trials are mild. Skin irritation, redness, and occasional contact sensitivity at higher concentrations. The more interesting adverse pattern comes from the community: "copper uglies." This is paradoxical skin worsening (sagging, accelerated wrinkling) caused by MMP-1 matrix metalloproteinase upregulation outpacing collagen synthesis. It happens most often with topical overuse or aggressive post-microneedling application. The fix is simple: drop to 1% concentration and wait 48 to 72 hours after microneedling before applying. Injectable side effects are dominated by injection site reactions. Burning and stinging from the copper ions is the number one complaint in community threads. Diluting with more bacteriostatic water, using a 31-gauge needle, and applying a cold compress for 60 seconds post-injection helps. Site rotation matters; no location should get more than one injection per week. Poor rotation leads to lipodystrophy (localized fat atrophy), which is harder to reverse than it sounds. At doses above 1.5 mg/day, some users report nausea and metallic taste. These are dose-dependent and resolve with reduction. Reconstituted stability is limited to two to three weeks refrigerated. Potency drops 15 to 30% by week four according to community tracking. The mcg versus mg calculation error is a real hazard for beginners; GHK-Cu vials are labeled in mg but doses are discussed in mcg. 1 mg equals 1,000 mcg. Getting this wrong by a factor of 1,000 is not theoretical; it's the most common beginner mistake in the community. Contraindications: Wilson's disease or copper metabolism disorders. Known hypersensitivity to GHK-Cu or copper compounds. Pregnancy or breastfeeding (no safety data). Hemochromatosis. Active malignancy without oncologist clearance. Severe kidney or liver dysfunction. Drug interactions: copper-chelating agents (penicillamine, trientine) reduce bioavailability by 60 to 80%. Zinc above 50 mg/day competes at copper transport sites. High-concentration topical vitamin C (15%+) chelates copper; separate application by two or more hours. Immunosuppressants may interact with the healing response; consult a prescriber. |
Key Differences
- Epithalon activates telomerase to lengthen telomeres for cellular longevity; GHK-Cu stimulates collagen and activates gene repair pathways.
- Epithalon is run in short cycles (10-20 days) every 4-6 months; GHK-Cu can be used continuously.
- GHK-Cu has topical applications for skin; Epithalon is injection-only.
- Epithalon targets aging at the DNA level; GHK-Cu targets tissue repair and gene expression.
When to Choose Epithalon
- DNA-level anti-aging and telomere preservation is the goal
- You prefer short, infrequent cycles
- Cellular longevity and lifespan extension are priorities
- You want to complement other anti-aging peptides
When to Choose GHK-Cu
- Skin quality, collagen, and wound healing are priorities
- You want both topical and injectable options
- Continuous use without cycling is preferred
- Tissue repair and gene expression modulation are goals
Can You Stack Epithalon + GHK-Cu?
Epithalon + GHK-Cu is the core of the anti-aging stack. Epithalon handles cellular longevity while GHK-Cu repairs tissue and gene expression: different mechanisms, no overlap.
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.